Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results Leukemia advance online publication, September 1 2017. doi:10.1038/leu.2017.247 Authors: T P Hughes, B Leber, F Cervantes, N Spector, R Pasquini, N C D Clementino, A P Schwarer, P E Dorlhiac-Llacer, F-X Mahon, D Rea, A Guerci-Bresler, S Kamel-Reid, I Bendit, S Acharya, T Glynos, D Dalal, S Branford & J H Lipton
Source: Leukemia - Category: Hematology Authors: Source Type: research